431 related articles for article (PubMed ID: 10338039)
21. Allogeneic blood stem cell transplantation in chronic myeloid leukaemia-chronic phase following conditioning with busulphan and cyclophosphamide: a follow up report.
Saikia TK; Parikh PM; Tawde S; Amare-Kadam PS; Rajadhyaksha S; Chhaya S
Natl Med J India; 2004; 17(2):71-3. PubMed ID: 15141598
[TBL] [Abstract][Full Text] [Related]
22. [Efficacy and toxicity of intravenous busulfan-based conditioning before allogeneic peripheral blood stem cell transplantation for leukemia].
Tong XZ; Xu DR; Zou WY; Li J; Luo SK; Peng AH; Zhang GC; Zheng D
Ai Zheng; 2007 Aug; 26(8):914-8. PubMed ID: 17697559
[TBL] [Abstract][Full Text] [Related]
23. CY/TBI-800 as a pretransplant regimen for allogeneic bone marrow transplantation for severe aplastic anemia using HLA-haploidentical family donors.
Tzeng CH; Chen PM; Fan S; Liu JH; Chiou TJ; Hsieh RK
Bone Marrow Transplant; 1996 Aug; 18(2):273-7. PubMed ID: 8864434
[TBL] [Abstract][Full Text] [Related]
24. Successful allogeneic hematopoietic stem cell transplantation using triple agent immunosuppression in severe aplastic anemia patients.
Kim HJ; Park CY; Park YH; Kim YJ; Kim DW; Min WS; Kim CC
Bone Marrow Transplant; 2003 Jan; 31(2):79-86. PubMed ID: 12621487
[TBL] [Abstract][Full Text] [Related]
25. Unrelated donor bone marrow transplantation for children with severe aplastic anemia: minimal GVHD and durable engraftment with partial T cell depletion.
Bunin N; Aplenc R; Iannone R; Leahey A; Grupp S; Monos D; Pierson G
Bone Marrow Transplant; 2005 Feb; 35(4):369-73. PubMed ID: 15640818
[TBL] [Abstract][Full Text] [Related]
26. Outcome in patients with Wiskott-Aldrich syndrome following stem cell transplantation: an analysis of 57 patients in Japan.
Kobayashi R; Ariga T; Nonoyama S; Kanegane H; Tsuchiya S; Morio T; Yabe H; Nagatoshi Y; Kawa K; Tabuchi K; Tsuchida M; Miyawaki T; Kato S
Br J Haematol; 2006 Nov; 135(3):362-6. PubMed ID: 17032176
[TBL] [Abstract][Full Text] [Related]
27. Modified conditioning regimen busulfan-cyclophosphamide followed by allogeneic stem cell transplantation in patients with multiple myeloma.
Zhang XH; Huang XJ; Liu KY; Xu LP; Liu DH; Chen H; Chen YH; Wang JZ; Han W; Lu DP
Chin Med J (Engl); 2007 Mar; 120(6):463-8. PubMed ID: 17439737
[TBL] [Abstract][Full Text] [Related]
28. [Effects and prognostic factors of HLA-matched sibling donor allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia].
Tong XZ; Li J; Tan EX; Zhang GC; Wu XY; Peng AH; Zheng D; Zou WY; Hong WD; Luo SK
Zhonghua Zhong Liu Za Zhi; 2006 Jul; 28(7):545-8. PubMed ID: 17147125
[TBL] [Abstract][Full Text] [Related]
29. Effect of altering administration order of busulphan and cyclophosphamide on the myeloablative and immunosuppressive properties of the conditioning regimen in mice.
Nilsson C; Forsman J; Hassan Z; Abedi-Valugerdi M; O'Connor C; Concha H; Jansson M; Hassan M
Exp Hematol; 2005 Mar; 33(3):380-7. PubMed ID: 15730862
[TBL] [Abstract][Full Text] [Related]
30. Busulfan and cyclophosphamide as a preparative regimen for allogeneic blood and marrow transplantation in patients with non-Hodgkin's lymphoma.
Kiss TL; Panzarella T; Messner HA; Meharchand J; Reddy V; Schimmer AD; Lipton JH
Bone Marrow Transplant; 2003 Jan; 31(2):73-8. PubMed ID: 12621486
[TBL] [Abstract][Full Text] [Related]
31. Improved results of allogeneic bone marrow transplantation for advanced hematologic malignancy using busulfan, cyclophosphamide and etoposide as cytoreductive and immunosuppressive therapy.
Vaughan WP; Dennison JD; Reed EC; Klassen L; McGuire TR; Sanger WG; Kumar PP; Warkentin PI; Gordon BG; Bierman PJ
Bone Marrow Transplant; 1991 Dec; 8(6):489-95. PubMed ID: 1790429
[TBL] [Abstract][Full Text] [Related]
32. Myeloablative intensified conditioning regimen with in vivo T-cell depletion (ATG) followed by allografting in patients with advanced multiple myeloma. A phase I/II study of the German Study-group Multiple Myeloma (DSMM).
Kröger N; Einsele H; Wolff D; Casper J; Freund M; Derigs G; Wandt H; Schäfer-Eckart K; Wittkowsky G; Schmitz N; Krüger W; Zabelina T; Renges H; Ayuk F; Krüll A; Zander A;
Bone Marrow Transplant; 2003 Jun; 31(11):973-9. PubMed ID: 12774047
[TBL] [Abstract][Full Text] [Related]
33. Complete substitution of cyclophosphamide by fludarabine and ATG in a busulfan-based preparative regimen for children and adolescents with beta-thalassemia.
Sauer M; Bettoni C; Lauten M; Ghosh A; Rehe K; Grigull L; Beilken A; Welte K; Sykora KW
Bone Marrow Transplant; 2005 Sep; 36(5):383-7. PubMed ID: 15995711
[TBL] [Abstract][Full Text] [Related]
34. Long-term follow-up of allogeneic stem cell transplantation in patients with severe aplastic anemia after conditioning with cyclophosphamide plus antithymocyte globulin.
Kröger N; Zabelina T; Renges H; Krüger W; Kordes U; Rischewski J; Schrum J; Horstmann M; Ayuk F; Erttmann R; Kabisch H; Zander AR
Ann Hematol; 2002 Nov; 81(11):627-31. PubMed ID: 12454700
[TBL] [Abstract][Full Text] [Related]
35. Fludarabine-based conditioning for allogeneic stem cell transplantation for multiply transfused patients with Fanconi's anemia.
George B; Mathews V; Shaji RV; Srivastava V; Srivastava A; Chandy M
Bone Marrow Transplant; 2005 Feb; 35(4):341-3. PubMed ID: 15640819
[TBL] [Abstract][Full Text] [Related]
36. Bone marrow transplantation in adults with thalassemia: Treatment and long-term follow-up.
Gaziev J; Sodani P; Polchi P; Andreani M; Lucarelli G
Ann N Y Acad Sci; 2005; 1054():196-205. PubMed ID: 16339666
[TBL] [Abstract][Full Text] [Related]
37. Hematopoietic stem cell transplantation for childhood myeloid malignancies after high-dose thiotepa, busulfan and cyclophosphamide.
Worth L; Tran H; Petropoulos D; Culbert S; Mullen C; Roberts W; Przepiorka D; Chan K
Bone Marrow Transplant; 1999 Nov; 24(9):947-52. PubMed ID: 10556952
[TBL] [Abstract][Full Text] [Related]
38. Bone marrow transplantation (BMT) in 14 children with severe sickle cell disease (SCD): the French experience. GEGMO.
Bernaudin F; Souillet G; Vannier JP; Plouvier E; Lemerle S; Michel G; Bordigoni P; Lutz P; Kuentz M
Bone Marrow Transplant; 1993; 12 Suppl 1():118-21. PubMed ID: 8374551
[TBL] [Abstract][Full Text] [Related]
39. Long-term outcomes of nonconditioned patients with severe combined immunodeficiency transplanted with HLA-identical or haploidentical bone marrow depleted of T cells with anti-CD6 mAb.
Patel NC; Chinen J; Rosenblatt HM; Hanson IC; Brown BS; Paul ME; Abramson SL; Ritz J; Shearer WT
J Allergy Clin Immunol; 2008 Dec; 122(6):1185-93. PubMed ID: 19084111
[TBL] [Abstract][Full Text] [Related]
40. Cord-blood transplants from unrelated donors in patients with Hurler's syndrome.
Staba SL; Escolar ML; Poe M; Kim Y; Martin PL; Szabolcs P; Allison-Thacker J; Wood S; Wenger DA; Rubinstein P; Hopwood JJ; Krivit W; Kurtzberg J
N Engl J Med; 2004 May; 350(19):1960-9. PubMed ID: 15128896
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
